Middle East & Africa Recombinant Protein Therapeutics Cdmo Market Size & Outlook
Middle East & Africa recombinant protein therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
MEA recombinant protein therapeutics cdmo market highlights
- The MEA recombinant protein therapeutics cdmo market generated a revenue of USD 641.6 million in 2023.
- The market is expected to grow at a CAGR of 12.4% from 2024 to 2030.
- In terms of segment, interferons was the largest revenue generating type in 2023.
- Growth Hormones is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 641.6 million |
| Market revenue in 2030 | USD 1,454.7 million |
| Growth rate | 12.4% (CAGR from 2023 to 2030) |
| Largest segment | Interferons |
| Fastest growing segment | Growth Hormones |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
| Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.1% of the global recombinant protein therapeutics cdmo market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 13,871.8 million by 2030.
Interferons was the largest segment with a revenue share of 21.46% in 2023. Horizon Databook has segmented the Middle East & Africa recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
The recombinant protein therapeutics CDMO market in MEA is expected to witness remunerative growth over the forecast period. The regulatory amendments and government initiatives to boost the pharmaceutical industry are anticipated to fuel market growth. Moreover, in the presence of tax breaks, domestic manufacturing and foreign investments are expected to increase in special economic zones, indirectly facilitating the recombinant protein therapeutics CDMO market in this region.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Recombinant Protein Therapeutics CDMO Market Scope
Recombinant Protein Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
MEA recombinant protein therapeutics cdmo market size, by country, 2018-2030 (US$M)
Middle East & Africa Recombinant Protein Therapeutics CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
